Clarity (ASX:CU6) get clear sight on prostate treatment
Clarity Pharmaceuticals has achieved a significant breakthrough in the treatment of prostate cancer in both children and adults.
Prostate cancer was the most commonly diagnosed cancer in Australia in 2018. It is estimated that it will remain the most commonly diagnosed cancer in 2022.
In 2018, there were 21,853 new cases of prostate cancer diagnosed in Australia. In 2022, it is estimated that 24,217 new cases of prostate cancer will be diagnosed in Australia.
In 2022, it is estimated that a male has a 1 in 6 (or 17%) risk of being diagnosed with prostate cancer by the age of 85.
In their SECuRE trial, the first participant of cohort 3 received the highest dose level (12GBq) of 64Cu/67Cu SAR-bisPSMA.
Cohort 2 has recently been completed with 3 participants receiving therapy with 67Cu SAR-bisPSMA at the dose level of 8GBq, all of whom experienced a reduction in Prostate Specific Antigen (PSA) levels of over 50% in just a few weeks after a single dose.
Notably, no adverse side effects have been reported from any trial participants.
Cu SAR-bisPSMA PET/CT imaging before and after a single cycle of 8GBq 67Cu SAR-bisPSMA (cohort 2)
They are recruiting more US clinical site participants for cohort 3 at the highest dose level (12GBq).
Clarity’s Executive Chairperson, Dr Alan Taylor, said its solution for better and more accessible prostate cancer therapy is in high demand, as shown by the swift recruitment process for the trial’s dose escalation phase.
“Results from cohort 2 are incredibly exciting, and we look forward to seeing data from the increased dosing of 12GBq as well as discovering the potential positive effects of multi-dosing on prostate cancer patients,”
“We look forward to sharing more data on 67Cu SAR-bisPSMA as we continue to recruit participants into the SECuRE trial and progress on our path towards commercialisation with the ultimate goal of improving treatment outcomes for people with cancer.”
Prostate cancer was the most commonly diagnosed cancer in Australia in 2018. It is estimated that it will remain the most commonly diagnosed cancer in 2022.
In 2018, there were 21,853 new cases of prostate cancer diagnosed in Australia. In 2022, it is estimated that 24,217 new cases of prostate cancer will be diagnosed in Australia. In 2022, it is estimated that a male has a 1 in 6 (or 17%) risk of being diagnosed with prostate cancer by the age of 85.
$2.25